NCT04486157View on ClinicalTrials.gov

Bioequivalence and Safety Study of IN-A012 and Akynzeo Capsules in Male and Female Healthy Korean Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

March 18, 2021

Primary Completion Date

April 26, 2021

Study Completion Date

May 10, 2021

Conditions
Healthy
Interventions
DRUG

IN-A012

The subjects will be given IN-A012 by Intravenous infusion over 30 minutes.

DRUG

Akynzeo 300Mg-0.5Mg Capsule

The subjects will be administrated Akynzeo by Orally with water.

Trial Locations (1)

Unknown

Catholic Univ. of Seoul St. Mary's Hospital, Seoul

Sponsors
All Listed Sponsors
lead

HK inno.N Corporation

INDUSTRY

NCT04486157 - Bioequivalence and Safety Study of IN-A012 and Akynzeo Capsules in Male and Female Healthy Korean Subjects | Biotech Hunter | Biotech Hunter